Influence of probiotics on inflammatory bowel disease

Author(s)

Claire W.E.; Independent researcher, Montpellier, France

Abstract

Inflammatory bowel disease (IBD) is one of the crucial immune-mediated inflammatory diseases in which an imbalance occurs within the cellular inflammatory pathways. This article takes a look at what IBD is and the potentials of probiotic use in eradicating or curbing IBD, as well as its particular possible protective influence.

Keywords

probiotics; inflammatory; immune-mediated

Cite this paper

Claire, W. E. (2021), Influence of probiotics on inflammatory bowel disease, IRESPUB Journal of Life Sciences. Volume 1, Issue 1, Sep-Oct 2021, Page 14-22

References

[1] Kuek, A., Hazleman, B. L., & Östör, A. J. (2007). Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgraduate medical journal, 83(978), 251-260.

[2] Klemenak, M., Dolinšek, J., Langerholc, T., Di Gioia, D., & Mičetić-Turk, D. (2015). Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease. Digestive diseases and sciences, 60(11), 3386-3392.

[3] Lee, S. R., Kim, S., Park, C. E., Lee, J. H., & Lee, D. H. (2019). Effect of Korean medicine as add-on therapy to phototherapy for psoriasis: Two case reports. Medicine, 98(11).

[4] Nie, N., Bai, C., Song, S., Zhang, Y., Wang, B., & Li, Z. (2020). Bifidobacterium plays a protective role in TNF-α-induced inflammatory response in Caco-2 cell through NF-κB and p38MAPK pathways. Molecular and cellular biochemistry, 464(1), 83-91.

[5] Sales-Campos, H., Soares, S. C., & Oliveira, C. J. F. (2019). An introduction of the role of probiotics in human infections and autoimmune diseases. Critical reviews in microbiology, 45(4), 413-432.

[6] Mao, L., Kitani, A., Strober, W., & Fuss, I. J. (2018). The role of NLRP3 and IL-1β in the pathogenesis of inflammatory bowel disease. Frontiers in immunology, 9, 2566.

[7] Galipeau, H. J., Caminero, A., Turpin, W., Bermudez-Brito, M., Santiago, A., Libertucci, J., et al. (2021). Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. Gastroenterology. https://doi.org/10.1053/j.gastro.2020.12.004

[8] Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., … & Huttenhower, C. (2019). Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 569(7758), 655-662.

[9] Gkouskou, K., Deligianni, C., Tsatsanis, C., & Eliopoulos, A. G. (2014). The gut microbiota in mouse models of inflammatory bowel disease. Frontiers in cellular and infection microbiology, 4, 28.

[10] Celiberto, L. S., Bedani, R., Rossi, E. A., & Cavallini, D. C. U. (2017). Probiotics: the scientific evidence in the context of inflammatory bowel disease. Critical reviews in food science and nutrition, 57(9), 1759-1768.

[11] Nitzan, O., Elias, M., Peretz, A., & Saliba, W. (2016). Role of antibiotics for treatment of inflammatory bowel disease. World journal of gastroenterology, 22(3), 1078.

[12] Yan, P. G., & Li, J. N. (2020). Advances in the understanding of the intestinal micro-environment and inflammatory bowel disease. Chinese medical journal, 133(7), 834.

[13] Ashaolu, T. J., & Fernández-Tomé, S. (2021). Gut mucosal and adipose tissues as health targets of the immunomodulatory mechanisms of probiotics. Trends in Food Science & Technology, 112, 764–779. doi:10.1016/j.tifs.2021.04.040

[14] Wang, Y. N., Meng, X. C., Dong, Y. F., Zhao, X. H., Qian, J. M., Wang, H. Y., & Li, J. N. (2019). Effects of probiotics and prebiotics on intestinal microbiota in mice with acute colitis based on 16S rRNA gene sequencing. Chinese medical journal, 132(15), 1833.

[15] Je, I. G., Lee, D. G., Jeong, D. G., Hong, D., Yoon, J. M., Moon, J. S., & Park, S. (2018). The probiotic, ID-JPL934, attenuates dextran sulfate sodium-induced colitis in mice through inhibition of proinflammatory cytokines expression. Journal of medicinal food, 21(9), 858-865.

[16] Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009). The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology, 7(11), 1202-1209.

[17] Tursi, A., Brandimarte, G., Giorgetti, G. M., Forti, G., Modeo, M. E., & Gigliobianco, A. (2004). Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medical science monitor, 10(11), PI126-PI131.

[18] Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., … & Gasbarrini, A. (2010). Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL# 3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. The American journal of gastroenterology, 105(10), 2218.

[19] Fedorak, R. N., Feagan, B. G., Hotte, N., Leddin, D., Dieleman, L. A., Petrunia, D. M., … & Madsen, K. (2015). The probiotic VSL# 3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clinical Gastroenterology and Hepatology, 13(5), 928-935.

[20] Van Gossum, A., Dewit, O., Louis, E., de Hertogh, G., Baert, F., Fontaine, F., … & Franchimont, D. (2007). Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo-caecal resection. Inflammatory bowel diseases, 13(2), 135-142.

[21] Steed, E., Balda, M. S., & Matter, K. (2010). Dynamics and functions of tight junctions. Trends in cell biology, 20(3), 142-149.

[22] Fan, H., Du, J., Liu, X., Zheng, W. W., Zhuang, Z. H., Wang, C. D., & Gao, R. (2019). Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease. The Turkish Journal of Gastroenterology, 30(8), 680.

[23] Song, H., Wang, W., Shen, B., Jia, H., Hou, Z., Chen, P., & Sun, Y. (2018). Pretreatment with probiotic Bifico ameliorates colitis‐associated cancer in mice: Transcriptome and gut flora profiling. Cancer science, 109(3), 666-677.